Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 107-114

  Komaba, Hirotaka ^a   Kakuta, Takatoshi ^b   Suzuki, Hajime ^c   Hida, Miho ^d   Suga, Takao ^a   Fukagawa, Masafumi ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^c Medical Corporation Kuratakai   (Japan)

^d Showakai Hospital   (Japan)

Author keywords

hemodialysis; hyperphosphatemia; lanthanum carbonate; survival

Indexed keywords

22 OXACALCITRIOL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCITRIOL; CALCIUM CARBONATE; LANTHANUM CARBONATE; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR ACTIVATOR; LANTHANUM;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL; AGED; BLOOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; PHOSPHORUS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84922464212     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu335     Document Type: Article

References (33)

1. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity inmaintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
2. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
3. Taniguchi M, Fukagawa M, Fujii N et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 2013; 17: 221-228
4. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17
5. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154
6. Chen NX, ONeill KD, Duan D et al. Phosphorus and uremic serum upregulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724-1731
7. Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113): S1-S130
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
9. Fukagawa M, Yokoyama K, Koiwa F et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013; 17: 247-288
10. Hutchison AJ. Oral phosphate binders. Kidney Int 2009; 75: 906-914
11. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362: 1312-1324
12. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanumcarbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100: c8-c19
13. Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2008; 12: 55-61
14. Goto S, Komaba H, Moriwaki K et al. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 2011; 6: 1375-1384
15. Toussaint ND, Lau KK, Polkinghorne KR et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton) 2011; 16: 290-298
16. Payne RB, Little AJ, Williams RB et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4: 643-646
17. Nakai S, Suzuki K, Masakane I et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 2010; 14: 505-540
18. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
19. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
20. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441
21. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137
22. Qunibi W, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965
23. Kakuta T, Tanaka R, Hyodo T et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating adVanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011; 57: 422-431
24. Jamal SA, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-Analysis. Lancet 2013; 382: 1268-1277
25. Wilson R, Zhang P, Smyth M et al. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009; 25: 3021-3028
26. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-396
27. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101
28. Cannata-Anda JB, Fernndez-Martn JL, Locatelli F et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998-1008
29. Lynch KE, Lynch R, Curhan GC et al. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 620-629
30. Shigematsu T, Negi S. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant 2102; 27: 1050-1054
31. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
32. Kazama JJ. Oral phosphate binders: history and prospects. Bone 2009; 45 (Suppl 1): S8-S12
33. Wang S, Anum EA, Ramakrishnan K et al. Reasons for phosphate binder discontinuation vary by binder type. J Ren Nutr 2014; 24: 105-109